This review provides a comprehensive analysis of IDO1-targeted therapeutic development, examining both the clinical experience with conventional inhibitors and the emerging potential of PROTAC-based degraders, while discussing their implications for the future of cancer immunotherapy. This evidence concerns the gene IDO1 and cancer.